Introduction
Type 2 diabetes mellitus (T2DM) is rising in incidence worldwide and constitutes a major public health burden (1) . T2DM is characterized by hyperglycemia and is caused by progressive peripheral insulin resistance and deficient insulin secretion from pancreatic β cells. Adipose tissue macrophages (ATMs) are considered crucial players that link obesity with insulin resistance and T2DM (2, 3) . This is underscored by the fact that proinflammatory cytokines secreted from ATMs induce insulin resistance by a number of different mechanisms (4, 5) . In line with these observations, several studies that target ATMs to attenuate the secretion of proinflammatory cytokines have shown beneficial effects with respect to insulin resistance (6, 7) . Over the last years, several G proteincoupled receptors (GPCRs) have emerged as critical regulators of ATM function (8) (9) (10) (11) (12) (13) (14) , rendering them highly attractive as targets for drug development.
G protein-coupled bile acid receptor 1 (GPBAR1; also known as GPR131, and referred to herein as TGR5) is a bile acid-responsive (BA-responsive) GPCR that, upon activation, triggers cAMPmediated downstream signaling. TGR5 is widely distributed and coordinates a large spectrum of biological processes, including bile homeostasis (15) (16) (17) (18) (19) , gallbladder relaxation (20, 21) , intestinal motility (22) (23) (24) , and BA-induced itch and analgesia (25) . Emerging evidence indicates that activation of the receptor confers protection against diet-induced diabesity via different cell-based mechanisms. TGR5 improves energy metabolism and glucose homeostasis via processes involving local thyroid hormone activation and glucagon-like peptide-1 (GLP-1) secretion (26, 27) . The contribution of TGR5 in GLP-1-induced insulin secretion is further underscored by the finding that BA sequestrants boost GLP-1 secretion in a TGR5-dependent manner (28, 29) . Enhanced TGR5 signaling is also associated with reduced liver steatosis (26) and improved pancreatic β cell function (26, 30) .
TGR5 is also expressed in cells of the hematopoietic system, such as monocytes and macrophages, and confers potent antiinflammatory properties in vitro and in vivo (31) (32) (33) (34) (35) (36) . Recent work from our laboratory revealed that the immune-suppressive actions of TGR5 in macrophages contribute to the prevention of the atherosclerotic process (34) . Because chronic, low-grade inflammation is a hallmark not only of atherosclerosis, but also of obesity and T2DM, we speculated that the immune-regulatory functions of TGR5 may also affect some of the metabolic abnormalities acquired during the onset of obesity and obesity-induced insulin resistance.
In the current study, we investigated the properties of macrophage TGR5 in the context of adipose tissue inflammation and associated diabesity. We found that Tgr5-deficient bone marrow chimeric mice (referred to herein as Tgr5 bm-/-mice) and myeloid cell-specific Tgr5-knockout mice (LysM-Cre Tgr5 fl/fl mice) with diet-induced obesity developed insulin resistance along with exacerbated inflammation in adipose tissue. Using these genetic models, we demonstrated that deletion of TGR5 in macrophages was associated with increased chemokine expression and migration, which was partly caused by impaired activation of AKT-mTOR complex 1 (AKT-mTORC1) and translation of the liver inhibitory protein (LIP) isoform of the transcription factor CCAAT/enhancer binding protein β (C/EBPβ). The unanticipated link between TGR5 and the AKT-mTOR-LIP axis highlights a new mechanism in macrophages that contributes to the antidiabetic effects of TGR5 activators.
The bile acid-responsive G protein-coupled receptor TGR5 is involved in several metabolic processes, and recent studies suggest that TGR5 activation may promote pathways that are protective against diet-induced diabetes. Here, we investigated the role of macrophage-specific TGR5 signaling in protecting adipose tissue from inflammation and associated insulin resistance. Examination of adipose tissue from obese mice lacking macrophage Tgr5 revealed enhanced inflammation, increased chemokine expression, and higher macrophage numbers compared with control obese animals. Moreover, macrophage-specific deletion of Tgr5 exacerbated insulin resistance in obese animals. Conversely, pharmacological activation of TGR5 markedly decreased LPS-induced chemokine expression in primary macrophages. This reduction was mediated by AKT-dependent activation of mTOR complex 1, which in turn induced the differential translation of the dominant-negative C/EBPβ isoform, liver inhibitory protein (LIP). Overall, these studies reveal a signaling pathway downstream of TGR5 that modulates chemokine expression in response to high-fat diet and suggest that targeting this pathway has the potential to be therapeutically exploited for prevention of chronic inflammatory diseases and type 2 diabetes mellitus.
TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation of leukocyte TGR5 in glucose homeostasis and insulin responsiveness. We performed bone marrow transplantations to generate chimeric C57BL/6J mice carrying bone marrow of either Tgr5 WT or Tgr5-knockout mice (referred to herein as Tgr5 bm+/+ and Tgr5 bm-/-mice, respectively). Genotyping of the Tgr5 allele in circulating
Results

Tgr5
bm-/-mice display worsened high-fat diet-induced insulin resistance. Earlier studies have shown that TGR5 protects against glucose intolerance and insulin resistance induced by high-fat diet (HFD) (26) . In the current study, we set out to determine the role (G-I) Western blot of phospho-AKT (P-AKT, Ser473), total AKT, and HSP90 in (G) liver, (H) gastrocnemius muscle, and (I) eWAT of HFD-fed Tgr5 bm+/+ and Tgr5 bm-/-mice injected i.p. with vehicle or insulin (1 U/kg; 10 min). Quantitative densitometry of Western blots is also shown. n = 6 per group. Results represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. genotype; # P < 0.001 vs. control, 2-tailed Student's t test or 1-or 2-way ANOVA with Bonferroni post-hoc analysis as appropriate.
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Exacerbated adipose tissue inflammation in Tgr5 bm-/-mice. Adipose tissue macrophages (ATMs) are a prominent source of inflammatory cytokines in obesity, which can directly trigger systemic insulin resistance (7, (37) (38) (39) Figure 1 , A and B). Food consumption and water intake were also comparable between the genotypes (Supplemental Figure 1 , B and C). Despite the lack of difference in fat content, plasma glucose levels decreased more slowly during insulin tolerance test (ITT) significantly induced in the adipose tissue of Tgr5 bm-/-mice ( Figure 2C ). Given the mild reduction in insulin sensitivity of Tgr5 bm-/-muscle ( Figure 1H ), we also tested the expression of the macrophage marker genes in gastrocnemius derived from ure 2, A and B). In line with these data, mRNA expression levels of the macrophage marker genes EGF-like module containing, mucin-like, hormone receptor-like sequence 1 (Emr1; hereafter F4/80), Cd68, and integrin αM (Itgam; hereafter Cd11b) were Figure 3F ), indicative of worsened insulin resistance in mice lacking macrophage TGR5. The difference in insulin resistance was highly dependent on HFD feeding, since chow diet-fed LysM-Cre Tgr5 fl/fl mice did not display any difference in ITT, insulin levels, or OGTT compared with controls (Supplemental Figure 3, B-D) .
To further confirm the role of macrophage TGR5 in modulating insulin responsiveness, we determined insulin-stimulated AKT phosphorylation in liver, muscle, and fat of HFD-fed Figure 3I ). These data indicate that Tgr5 deficiency in macrophages predominantly reduces insulin responsiveness in adipose tissue.
bm-/-and Tgr5 bm+/+ mice; however, no difference was found between the genotypes (Supplemental Figure 2A) .
We then performed FACS analysis on stromal vascular fraction (SVF) cells isolated from adipose tissue of bm-/-mice, whereas IL-6 (Il6), nitric oxide synthase 2, inducible (Nos2; hereafter iNos), and IL-12B (Il12b; also known as Il12) were unchanged or showed only a trend toward increase ( Figure 2J) .
Consistent with the FACS analysis of CD206 and CD301 (Figure 2 , F-I), gene expression of M2 markers, such as IL-10 (Il10), C-type lectin domain family 10, member A (Clec10a; hereafter Mgl1), chitinase 3-like 3 (Chi3l3; hereafter Ym1) and resistinlike α (Retnla; also known as Fizz1) was significantly attenuated in adipose tissue of Tgr5 bm-/-mice, whereas arginase 1 (Arg1), an M2 signature gene, was not changed ( Figure 2K ). In contrast to our findings in adipose tissue, M1 and M2 markers were not differentially expressed in gastrocnemius derived from Tgr5 bm-/-and Tgr5 bm+/+ mice, except for a slight increase in Il6 mRNA (Supplemental Figure 2 , B and C). Taken together, these results indicate Figure 4C and Supplemental Figure 3E ).
To assess whether the imbalance between M1 and M2 ATMs was also present in LysM-Cre Tgr5 fl/fl eWAT, we analyzed the extent of inflammation in this tissue. Expression of the M1 markers Tnfa, Cd11c, Il1b, Il6, and Il12b was significantly increased in eWAT of LysM-Cre Tgr5 fl/fl mice fed HFD, whereas iNos only showed a trend toward increase ( Figure 4D ). On the other hand, gene expression of M2 markers, such as Il10 and Mgl1, was significantly attenuated in LysM-Cre Tgr5 fl/fl eWAT, while Arg1, Ym1, and Retnla trended toward a decrease ( Figure 4E ). Taken together, these results indicate that macrophage TGR5 deficiency is characterized by an increase of proinflammatory M1 ATMs upon HFD feeding.
TGR5 activation does not affect M2 polarization. Next, we investigated whether TGR5 directly renders macrophages more susceptible for M2 polarization in vitro. We generated bone marrow-derived primary macrophages (BMDMs) and exposed the differentiated cells to the TGR5 agonist 6α-ethyl-23(S)-methylcholic acid (S-EMCA; hereafter INT-777) (26, 43, 44) and/or to IL-4, a Th2 cytokine well known to promote differentiation of alternative M2 macrophages (45) (46) (47) . As expected, IL-4 treatment induced M2 polarization; however, stimulation of BMDMs with INT-777, alone or together with IL-4, did not increase the expression of the M2 antiinflammatory genes Arg1, Il10, Ym1, Mgl1, and Retnla ( Figure 5, A-E) . In addition, Tgr5 transcript levels were not changed in BMDMs upon M1 or M2 polarization with LPS or IL-4, respectively ( Figure 5F ). These data indicate that activation of TGR5 in macrophages does not promote differentiation toward the M2 phenotype.
TGR5 deletion induces chemokine-mediated macrophage infiltration. The chemokine signaling network is also crucial in ATM function (48) . We therefore analyzed the expression of several chemokines and chemokine receptors in adipose tissue of primary macrophages to migrate in vitro toward CCL2, an effect that was not observed in Tgr5 -/-primary macrophages ( Figure 6E ). More importantly, the absence of TGR5 significantly increased the number of macrophages able to invade an implanted Matrigel plug in vivo ( Figure 6F ). Taken together, these data indicate that TGR5 deficiency is associated with enhanced chemokine expression that could mediate obesity-induced macrophage recruitment and activation in adipose tissue.
We then investigated whether TGR5 activation can directly regulate chemokine expression in vitro. Stimulation of Tgr5
-/-BMDMs with LPS induced similar expression levels of multiple chemokine genes, including Ccl2, Ccl3, Ccl4, Ccl5, Ccl7, TGR5 activation reduces chemokine expression through the AKTmTOR-LIP axis. Chemokine production is regulated by several transcription factors and nuclear receptors (49, 50) . We therefore investigated whether TGR5 modulation could regulate chemokine expression through one of these factors. Neither the absence of TGR5 nor its activation affected the expression of PPARγ (Pparg1), liver X receptor α (Lxra), liver X receptor β (Lxrb), or their target genes (Supplemental Figure 5, A-I ). We previously demonstrated that TGR5 stimulation inhibits NF-κB activity and has no effect on the proinflammatory component of the AP-1 complex, c-Jun (34) . In order to identify other mechanisms, we explored the role of C/EBPβ, another established regulator of chemokine expression (51) . The 3 C/EBPβ isoforms -full liver activating protein (LAP*), liver activating protein (LAP), and LIP -are translated from a single intron-less gene (52) . The smallest C/EBPβ isoform, LIP, lacks the N-terminal transactivation domain and acts as a dominant-negative regulator of the LAP isoform of C/EBPβ or of other interacting transcription Control of LIP expression is mediated by differential initiation of protein translation through the activity of eukaryotic translation initiation factors (eIFs) (54) . Previous studies have shown that mTOR enhances the level of accessible eIF-4E (57), thereby increasing the expression of the truncated C/EBPβ isoform LIP in an upstream ORF-dependent (uORF-dependent) manner (54) . In light of this mechanism, we sought to determine whether TGR5-dependent activation of the mTOR pathway could be responsible for the increase in LIP in our model. Stimufactors (52) (53) (54) (55) . We first investigated whether TGR5 could regulate C/EBPβ expression. In accordance with the proinflammatory role of C/EBPβ (56), stimulation of primary macrophages with LPS induced C/EBPβ expression, at both the mRNA and the protein level (Figure 7, A-C) . Notably, activation of TGR5 by INT-777 in LPS-treated BMDMs did not affect the levels of Cebpb mRNA, but reversed the ratio of C/EBPβ isoforms, marked by an increase in LIP protein (Figure 7, A-C) . These data indicate that TGR5 can inhibit the proinflammatory LAP transcription factor by inducing LIP expression (52). modulates chemokine expression via a mechanism involving AKT-mTOR-dependent induction of LIP expression.
Discussion
Here, we showed that specific deletion of TGR5 in mouse macrophages exacerbates HFD-induced insulin resistance without affecting body weight and adipose mass. We found that adipose tissue of Tgr5 bm-/-and LysM-Cre Tgr5 fl/fl mice is characterized by increased infiltration of proinflammatory M1 ATMs and enhanced expression of chemokines. Furthermore, we demonstrated that TGR5 activation reduces chemokine expression in macrophages via mTOR-dependent upregulation of the C/EBPβ isoform LIP and decreases ATM infiltration, thereby ameliorating obesityinduced insulin resistance.
Several lines of evidence point to an important role of ATMs in the development of systemic insulin resistance and glucose intolerance and in the progression of the metabolic syndrome (5, 39, 63 ). In the setting of obesity, proinflammatory cytokines and chemokines, 
contribute to the glucose-lowering actions of TGR5 (88), including stimulation of energy expenditure (27) , secretion of the incretin GLP-1 (26, 28, 29, 89) and direct stimulation of insulin secretion from isolated pancreatic islets (30) . Our present findings demonstrated that TGR5 activation can alter ATM function, thereby improving insulin action. These data indicate that the role of TGR5 in glucose homeostasis involves multiple tissues and processes.
In conclusion, we have elucidated a novel multicomponent TGR5-AKT-mTOR signaling pathway that induces differential translation of the C/EBPβ isoform LIP in macrophages. This axis links TGR5 tightly with obesity-induced insulin resistance through modulation of chemokine expression and ATM function. TGR5 activation in macrophages may hence be a promising approach to prevent insulin resistance and treat T2DM and associated inflammatory and metabolic disorders.
Methods
Animals. Mice were housed with ad libitum access to water and food and kept under a 12-hour dark/12-hour light cycle. The whole-body
Tgr5
-/-mouse model has been described previously (26) . then sacrificed 18 weeks after initiation of diet. Tgr5 deletion in the leukocytes was confirmed using the primers 5′-AGAGCCAAGAGGGA-CAATCC-3′ and 5′-TGGGTGAGTGGAGTCTTCCT-3′. Mouse phenotyping. Mouse body weight was assessed weekly. Food and water intake were measured manually over a 24-hour period. Body composition was analyzed by noninvasive monitoring of fat and lean masses using EchoMRI (Echo Medical Systems), as previously described (90) .
ITT was performed by measuring blood glucose following i.p. injection of insulin (0.5-0.75 U/kg) after a 5-hour fast. Blood glucose was determined by ACCU-CHEK glucose meters (Roche).
OGTT was performed by measuring blood glucose following oral administration of glucose (2 g/kg) after overnight fasting. Blood glucose was determined by ACCU-CHEK glucose meters (Roche), and plasma insulin levels were measured by specific ELISA kits (Crystal Chem), following the manufacturer's instructions.
To assess changes in insulin sensitivity, HOMA-IR (91) was calculated as (fasting plasma glucose × fasting serum insulin)/58.32.
Western blotting. For insulin-stimulated phospho-AKT analysis, mice were fasted overnight, and liver, gastrocnemius, and eWAT were collected 10 minutes after i.p. injection of insulin (1 U/kg) and snap frozen in liquid nitrogen.
Tissues and cells were lysed using RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 2 mM EDTA, and 50 mM NaF) supplemented with 1 mM PMSF and promarkers of M1 macrophages, recruit additional macrophages to the adipose tissue, thus reinforcing tissue inflammation and insulin resistance via a multitude of mechanisms (37, (64) (65) (66) . Knockout mouse studies have shown that CCR2 and its ligand CCL2 are pivotal in triggering obesity-induced insulin resistance and are required for accumulation of inflammatory macrophages in fat (67) (68) (69) (70) . CCL2 was also shown to increase macrophage content via ATM proliferation, in addition to its effect on blood monocyte recruitment (71) . We observed that Ccl2 expression, together with that of other chemokines and their receptors, was increased in the fat of HFD-fed mice lacking macrophage TGR5. This could be partially explained by the higher macrophage number in this tissue, together with a direct effect of TGR5 activation on Ccl2, Ccl3, and Ccl4 in primary macrophages. We therefore propose that the reduced expression of Ccl2, Ccl3, and Ccl4 subsequent to TGR5 activation attenuates ATM accumulation and enhances insulin sensitivity.
Our finding of impaired induction of the negative C/EBPβ isoform LIP provides an explanation for the elevated chemokine expression in Tgr5 -/-macrophages and Tgr5 bm-/-and LysM-Cre Tgr5 fl/fl adipose tissue. We demonstrated that the TGR5-mediated selective increase in LIP was achieved through alternative translation triggered by enhanced AKT-mTOR signaling. Indeed, mTOR signaling affects the activity of the translation initiation factor eIF-4E, which is involved in C/EBPβ isoform switching (54, 72) . Inhibition of mTOR/mTORC1 by rapamycin shifted the C/EBPβ isoform ratio in favor of LAP. The importance of this mTOR-dependent switch in C/EBPβ isoform translation has been previously demonstrated in osteoblast and osteoclast differentiation (73, 74) , bone formation (75), cancer progression (53, 76, 77) , liver regeneration (78) , and inflammation (79) . Although C/EBPβ-null mice have been generated to address the function of C/EBPβ in vivo (80), those mice lack both LIP and LAP isoforms, and are hence not appropriate to dissect the specific function of each isoform. Selective deletion of the dominant-negative isoform LIP has been achieved by generating a mouse line deficient for the C/EBPβ uORF initiation codon that fails to initiate LIP translation (C/EBPβ ΔuORF mice) (81) . In this mouse line, lack of LIP expression exacerbates the induction of C/EBPβ target genes in a model of partial hepatectomy-induced inflammation. Together, these results suggest that TGR5-mediated LIP induction contributes to the suppression of inflammatory markers that are normally boosted by other transcription factors, including the LAP isoform of C/EBPβ. As the b-ZIP domain of LAP has been reported to interact with the Rel homology domain of NF-κB and to enhance NF-κB-dependent transcription (82) (83) (84) (85) , the dominant-negative C/EBPβ isoform LIP could also blunt NF-κB activation and further decrease the inflammatory response. Several studies demonstrate that TGR5 activation inhibits NF-κB signaling through pleiotropic mechanisms, including IκBα, CREB, and c-Fos phosphorylation (32, 34, 36) . Our present data add modulation of LIP translation to the means by which TGR5 could reduce the inflammatory actions of NF-κB.
Based on our findings, we propose that macrophage TGR5 contributes to the systemic insulin-sensitizing effects of BAs. BAs are well-characterized endogenous TGR5 ligands (44) that are robustly induced in human plasma after a glucose challenge (86) and correlate with enhanced insulin sensitivity (26, 87 24 hours, were loaded into the upper portion of a 6.5-mm Transwell with 8.0-μm Pore Polycarbonate Membrane Insert (Corning); DMEM with CCL2 (100 ng/ml) was placed in the lower chamber. After 6 hours of migration, cells were fixed in Shandon Formal Fixx (Thermo Scientific). Cells were then stained with DAPI and counted.
Matrigel plug assay. In total, 700 μl growth factor-reduced Matrigel, with 200 ng/ml basic fibroblast growth factor (Invitrogen) and 60 U/ml heparin (Sigma-Aldrich) added, was injected s.c. into Tgr5 +/+ and Tgr5 -/-mice. After 7 days, the Matrigel plug was removed, fixed in Shandon Formal Fixx (Thermo Scientific), and processed for immunohistochemistry using a MAC3 antibody (BD Biosciences -Pharmingen).
Statistics. Prism software (GraphPad) was used for statistical analysis. All results were expressed as mean ± SEM. P values were calculated by 2-tailed Student's t test or 1-or 2-way ANOVA with Bonferroni posthoc analysis as appropriate. For analysis between genotypes, a P value less than 0.05 was considered significant; for analysis compared with control, P values less than 0.001 (extremely significant) are indicated.
Study approval. All animal experiments were carried out according to national Swiss and EU ethical guidelines and were approved by the local animal experimentation committee of the Canton de Vaud (license no. 2614).
tease and phosphatase inhibitor cocktails (Roche). Lysates were incubated on ice and cleared by centrifugation at 18,500 g for 15 minutes at 4°C. Protein concentration was determined by the Lowry method, and samples were analyzed for immunoblotting using standard procedures. Antibodies against phospho-AKT (Ser473) (Cell Signaling), AKT (Cell Signaling), phospho-mTOR (Ser2448) (Cell Signaling), mTOR (Cell Signaling), phospho-p70S6K (Thr389) (Cell Signaling), p70S6K (Cell Signaling), phospho-4E-BP1 (Thr37/46) (Cell Signaling), 4E-BP1 (Cell Signaling), C/EBPβ (Santa Cruz Biotechnology), and HSP90 (BD Biosciences) were used for Western blot analysis.
Histology and immunostaining. H&E staining was performed as described previously (92) . Antibodies against F4/80 (Abcam) were used for immunohistochemistry to detect macrophages. F4/80 staining was visualized using HRP-conjugated goat anti-rat IgG antibodies (Jackson) and DAB substrate (Sigma-Aldrich). Microphotographs were taken on wide-field microscopes (Olympus) with a CCD camera. Average adipocyte size was quantified by measuring a total of 150 adipocytes in the eWAT using ImageJ.
qRT-PCR. RNA was isolated from tissues and cells using TRI Reagent (Ambion), after which cDNA was synthesized (Qiagen). Realtime qRT-PCR was performed using SYBR green (Roche) in the Lightcycler 480 II (Roche). All mRNA expression levels were corrected for expression of the housekeeping gene 36B4 or β2-microglobulin.
FACS analysis. Epididymal fat pads were weighed, rinsed in phosphate-buffered saline and minced in HBSS. Tissue suspensions were treated with collagenase (Sigma-Aldrich) at a final concentration of 1 mg/ml for 80 minutes at 37°C with shaking. The cell suspensions were filtered through a 70-μm filter and centrifuged at 300 g for 5 minutes. Stromal vascular cells were incubated in staining buffer (HBSS plus 25 mM HEPES) containing antibodies to block the Fc receptor (Fc γ RIIb/CD16-2; derived from hybridoma 2.4G2) and stained with a combination of the following antibodies: PE-Cy5.5-labeled CD45 (EBioscience), FITClabeled Ly6G (MACS), BV421-labeled Siglec-F (BD Horizon), PE-Cy7-labeled CD11b (EBioscience), PE-labeled CD301 (BioLegend), PElabeled CD206 (Biolegend), APC-labeled F4/80 (Ebioscience). FACS analysis was performed on a Cyan analyzer (Beckman Coulter), and FlowJo software was used for data analysis.
Derivation of macrophages and stimulation. BMDMs were isolated from the femurs and tibias of sibling 8-to 10-week-old Tgr5 +/+ and Tgr5 -/-mice. Cells were plated on bacteriological plastic plates in macrophage growth medium consisting of RPMI-1640 (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 1× nonessential amino acids (Invitrogen), 5 mM penicillin/streptomycin (Invitrogen), and 10% heat-inactivated fetal bovine serum (GE Healthcare) supplemented with 10% L-cell-conditioned medium as a source of CSF-1. After 1 day, nonad-
